MIT Technology ReviewUS Doctors Plan to Treat Cancer Patients Using CRISPRMIT Technology ReviewThe first human test in the U.S. involving the gene-editing tool CRISPR could begin at any time and will employ the DNA cutting technique in a bid to battle … Continue reading
|
Commercially Promising Stem Cell Research Projects Land State Funding
Twin Cities Business Magazine This new method is a form of cell transplantation utilizing the patient’s own cells, so it does not require immunosuppressive drugs. Dr. Troy Lund, University of Minnesota Stem Cell Institute. Dr. Lund’s research focuses improving the outcomes of … |
|
Lucigen Inks Global Distribution Deals
GenomeWeb The Madison, Wisconsin-based firm’s products support drug and therapeutic discovery, personalized medicine, synthetic biology, and point-of-care diagnostics. Last year Lucigen was also named sole distributor of Illumina’s Epicentre genomics kits … |
Washington Post |
Targeting Biotech’s 1%, China Speeds Into Gene Therapy: Gadfly
Washington Post China wants to go big on biotech and already is marching into experimental gene therapy. Last year marked a milestone in cancer treatment: In August, the U.S. FDA approved Novartis AG’s Kymriah, a CAR-T therapy for children with acute lymphoblastic … |
|
China’s Great Leap Into Biotech
Bloomberg China wants to go big on biotech and already is marching into experimental gene therapy. Last year marked a milestone in cancer treatment: In August, the U.S. FDA approved Novartis AG’s Kymriah, a CAR–T 1 therapy for children with acute lymphoblastic … |
Seeker |
Human Immunity to Cas9 Could Threaten CRISPR’s Future
Seeker One reason is to speed the development of Cas9 alternatives that aren’t derived from pathogenic bacteria. Promising results have already been achieved with a protein called Cpf1, so even if Cas9 immunity proves a serious issue, it doesn’t mean the end … |
Seeker |
Human Immunity to Cas9 Could Threatens CRISPR’s Future – Seeker
Seeker New data shows that humans carry antibodies and even T-cells that target the Cas9 protein at the heart of CRISPR technology. |